Imputed interest on extended supplier credit for capital equipment purchases

Failing to separate the financing component from extended, nominally interest-free supplier credit overstates the cost of PP&E (and future depreciation), understates finance costs in the income statement, and misclassifies what is economically a loan as ordinary trade payables - distorting leverage and interest-cover ratios that lenders and rating agencies rely on. Because capital equipment purchases on extended terms are often large relative to total assets, even a single overlooked arrangement can materially misstate both the balance sheet split between PP&E/financial liabilities and the income statement split between depreciation and finance costs over several years.

Are the supplier's payment terms materially longer than normal trade credit for similar equipment purchases (e.g. interest-free terms of 2-5 years versus typical 30-90 days), signaling an embedded financing component? Is a cash-price equivalent stated in the contract, quoted by the supplier, or otherwise determinable by discounting the payment stream at a market rate reflecting the buyer's credit risk? Is the equipment measured at that cash-price equivalent (not the nominal payment total), with the difference recognized as a finance cost over the payment term?

1. Identify capital equipment purchases where the supplier's payment terms are materially longer than normal trade credit for similar purchases (e.g., interest-free terms of 2-5 years rather than the typical 30-90 days), signaling a possible embedded financing arrangement.
2. Determine whether a cash-price equivalent for the equipment is stated in the contract, quoted by the supplier for immediate payment, or otherwise observable/determinable (e.g., from price lists or comparable cash transactions).
3. If no explicit cash price is available, estimate it by discounting the total contractual payments to present value using a market rate of interest for similar credit (i.e., the rate the buyer would pay a bank or similar lender for a loan of comparable term, currency and credit risk).
4. Recognize the equipment at initial recognition at the cash-price-equivalent/present-value amount, not at the sum of the nominal future payments, and recognize a corresponding financial liability under IFRS 9 for that same amount.
5. Recognize the difference between the cash-price equivalent and the total nominal payments as interest expense, accreted over the credit period using the effective interest method (not straight-line, other than as a simplification where the difference is immaterial).
6. At each payment date, reduce the liability for the cash paid and record the interest accretion for the period, continuing until the liability is fully settled at the final payment.

Measurement basis: the equipment is measured on initial recognition at the cash-price equivalent (present value of the payment stream discounted at a market rate reflecting the buyer's credit risk and the arrangement's term/currency); the related liability is a financial liability under IFRS 9 initially measured at the same present value and subsequently measured at amortized cost using the effective interest method. Included: all contractual payments required under the extended-credit arrangement in the present-value calculation. Excluded: any separately identifiable maintenance, installation, training or warranty services bundled into the payment schedule, which should be measured and accounted for separately from the financing arrangement. Re-measurement triggers: none for the asset once initially capitalized (subject to normal depreciation and impairment); for the liability, the effective interest method automatically accretes the balance each period; a substantive modification of payment terms (e.g., rescheduling, rate change if any) requires reassessment of whether it is a modification or extinguishment of the liability under IFRS 9, with a corresponding remeasurement or derecognition.

Equipment capitalized at the cash-price equivalent, separately identifiable from the nominal contract price in supporting schedules; the supplier financing liability presented as a financial liability (split current/non-current based on scheduled payments) distinct from ordinary short-term trade payables; total imputed interest expense recognized in the period disclosed within finance costs, with the effective interest rate used; a maturity analysis of the remaining payments under the arrangement, consistent with IFRS 7 financial-instrument disclosure expectations; description of the judgment applied in determining the cash-price equivalent and the discount rate where not explicitly stated in the contract.

• Recording the full nominal payment schedule as the asset'
• s cost, overstating PP&
• E and understating interest expense over the credit term
• failing to identify a financing component in unusually long, nominally '
• interest-free'
• supplier payment terms, treating the whole arrangement as ordinary trade credit
• using an arbitrary or overly low discount rate (e.g., the entity'
• s overall weighted average cost of capital rather than a rate reflecting the specific credit risk and term of this arrangement), materially misstating the split between asset cost and interest
• applying straight-line amortization of the discount rather than the effective interest method when the difference is material, distorting the interest expense pattern across years
• not reassessing whether a modification of payment terms mid-arrangement (e.g., an extension granted by the supplier) requires remeasurement of the liability and a corresponding adjustment.